Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Working Capital Change in Working Capital Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Bioventus (BVS) Cash from Discontinued Operations (2022 - 2023)

Bioventus filings provide 2 years of Cash from Discontinued Operations readings, the most recent being 2169000.0 for Q2 2023.

On a quarterly basis, Cash from Discontinued Operations changed N/A to 2169000.0 in Q2 2023 year-over-year; TTM through Dec 2023 was 2169000.0, a 1.83% decrease, with the full-year FY2023 number at 2169000.0, down 1.83% from a year prior.
Cash from Discontinued Operations hit 2169000.0 in Q2 2023 for Bioventus, down from 1271000.0 in the prior quarter.
In the past five years, Cash from Discontinued Operations ranged from a high of 859000.0 in Q4 2022 to a low of 2169000.0 in Q2 2023.